Induction of neutralizing antibodies and Gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

Journal of Virology

Volumn 75, Issue 13, 2001, Pages 5879-5890

  Montefiori, D C ^a   Safrit, J T ^a   Lydy, S L ^a   Barry, A P ^a   Bilska, M ^a   Vo, H T T ^a   Klein, M ^a   Tartaglia, J ^a   Robinson, H L ^a   Rovinski, B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; PROTEINASE; RECOMBINANT DNA; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RHESUS MONKEY; SEROCONVERSION; T LYMPHOCYTE; VACCINE PRODUCTION; VIRUS PARTICLE;

ANIMALS; CROSS REACTIONS; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNIZATION; INTERFERON TYPE II; MACACA MULATTA; NEUTRALIZATION TESTS;

EID: 0034967872     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.13.5879-5890.2001     Document Type: Article

References (93)

1. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus
2. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
3. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
4. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals
5. Induction of immune responses to HIV-1 canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
6. HIV entry and tropism: The chemokine receptor connection
7. HIV-1 phenotypes classified by co-receptor usage
8. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand
9. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization
10. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by gp160 protein boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
11. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
12. The antibody response in HIV-1 infection
13. A vaccine for HIV type 1: The antibody perspective
14. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
15. Virologic and immunologic characterization of long-term survivors of HIV-1 infection
16. Characterization of primary isolate-like variants of simian-human immunodeficiency virus
17. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency type 1 isolates
18. Expression cloning of new receptors used by simian and human immunodeficiency viruses
19. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
20. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques
21. The role of mononuclear phagocytes in HTLV/LAV infection
22. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary, isolates of HIV-1
23. Serologic responses to candidate AIDS vaccines
24. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay
25. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
26. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
27. + T cell depletion in simian immunodeficiency virus-infected macaques
28. The recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates
29. Temporal association of cellular immune responses with initial control of viremia in primary human immunodeficiency virus type 1 syndrome
30. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
31. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
32. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
33. Progress in the development of an HIV-1 vaccine
34. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions
35. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
36. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
37. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
38. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
39. HIV type 1 transmission probabilities: Estimates from epidemiologic studies
40. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
41. Mechanism of human immunodeficiency virus type 1 (HIV-1) neutralization: Irreversible inactivation of infectivity by anti-HIV-1 antibody
42. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12
43. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 is independent of coreceptor usage
44. Toward an HIV-1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
45. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding region of gp120
46. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
47. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay
48. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
49. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates
50. Human trials of HIV-1 vaccines
51. A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1
52. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain
53. Recombinant modified vaccinia virus Ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques
54. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
55. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads
56. Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity
57. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term nonprogressive infection
58. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
59. Viral load and heterosexual transmission of human immunodeficiency virus type 1
60. Immunopathogenic events in the acute infection of rhesus monkeys with simian immunodeficiency virus of macaques
61. A role for carbohydrates in immune evasion in AIDS
62. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression
63. Immune control of HIV-1 following early treatment of acute infection
64. Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees
65. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: Implications for development of a cross-protective AIDS vaccine
66. Chemokine receptors as HIV coreceptors: Implications and interactions
67. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope gp120
68. Characterization of HIV-1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope
69. A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted cytotoxic T lymphocytes from two acute seroconversion patients
70. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: Soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120
71. + lymphocytes control viremia in simian immunodeficiency virus infection
72. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120
73. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1
74. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer
75. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
76. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1
77. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization
78. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
79. CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression
80. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of their coreceptor usage
81. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
82. + target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
83. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells
84. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope
85. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1
86. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission
87. CD8 lymphocytes can control HIV infection in vitro by suppressing virus replication
88. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus
89. The antigenic structure of the HIV gp120 envelope glycoprotein
90. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
91. + lymphocyte responses in acutely infected rhesus monkeys
92. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells